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Abstract
Background We assessed adherence to the European Society
of Medical Oncology (ESMO)/Multinational Association of
Supportive Care in Cancer recommendations for prophylaxis
of chemotherapy-induced nausea and vomiting (CINV) at our
institution.
Patients and methods The charts of 299 patients starting a
new chemotherapy between November 2008 and April
2009 were reviewed. Baseline characteristics and prophy-
laxis of CINV during the first cycle were recorded, and
adherence to ESMO recommendations was determined.
Chi-square tests and logistic regression were used to test for
predictors of adherence.
Results Prophylaxis of acute CINV was not adherent in 39%
of the patients: 39 of 54 patients with low emetogenic
chemotherapy had a serotonin antagonist, and 24 of 100 with
moderately emetogenic therapy had a neurokinin antagonist.
Nevertheless, 71% of the patients treated with highly
emetogenic therapy received the guideline-specified prescrip-
tion. Prophylaxis of delayed CINV was not adherent in 89%
of the patients: 101 of 125 patients with highly or moderately
emetogenic single-day chemotherapy received a serotonin
antagonist. Male gender (odds ratio (OR) 0.484, 95%
confidence interval (CI) 0.291–0.806; P=0.005) and hema-
tologic neoplasia (OR 2.151, 95% CI 1.19–3.887; P=0.011)
were independent predictors of non-adherence. Age (OR
0.981, 95% CI 0.964–0.998; P=0.029) and inpatient
treatment (OR 0.457, 95% CI 0.25–0.836; P=0.011)
indicated a lower risk of non-adherence.
Conclusion Contrary to older studies reporting frequent
omissions of corticosteroids, the current study demonstrated
significant overuse of serotonin antagonists for prophylaxis
of delayed CINV.
Keywords Chemotherapy . Nausea . Emesis . Supportive
care . Guidelines . Corticosteroids
Introduction
Medical guidelines are generally developed to define thera-
peutic standards resulting in the optimization of treatment.
Ideally, they should be evidence-based, economical, and
practicable and should rapidly adjust to medical progress.
Chemotherapy-induced nausea and vomiting (CINV) can be
prevented efficiently by corticosteroids, serotonin and neuro-
kinin antagonists, dopamine antagonists, and benzodiazepines
[1–5]. Although generally well tolerated, these drugs are
associated with potential side effects and interactions.
Adverse effects of corticosteroids are well-known, including
infection, hypertension, diabetes, edema, gastritis, psychosis,
and many more. Serotonin antagonists frequently cause
headache, dizziness, constipation, abdominal pain, and
fatigue. The neurokinin antagonist aprepitant is a substrate
and inhibitor of CYP3A4 and can interact with cytostatic
agents, corticosteroids, coumarins, oral contraceptives, and
other drugs. Serotonin and neurokinin antagonists are
associated with significant expense. To foster adequate
prophylaxis of CINV, many organizations have published
guidelines and recommendations, including the Multinational
Association of Supportive Care in Cancer (MASCC), the
American Society of Clinical Oncology (ASCO), the
National Comprehensive Cancer Network, the European
Society of Medical Oncology (ESMO), and others [6–12].
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The ESMO clinical recommendations are the basis for the
ESMO examination in medical oncology, which is required
for board certification in most European countries, including
Switzerland. ESMO recommendations are updated periodi-
cally and published in the Annals of Oncology.
The literature on the adherence to guidelines for
prophylaxis of CINV in clinical practice is limited. Only
few studies addressed this issue, and the results suggest that
guidelines are difficult to transfer to the clinic [13–17].
Therefore, we assessed the adherence to the ESMO
recommendations at our institution.
Methods
The study was approved by the Research Ethics
Committee of the Canton of Berne, Switzerland. Using
the electronic patient management system, we retro-
spectively identified all patients who received chemo-
therapy for the first time at our institution between
November 1, 2008 and April 30, 2009. We collected the
relevant baseline characteristics from the patient
records, including patient age, gender, cancer diagnosis,
chemotherapy, therapeutic intent, inpatient or outpatient
setting, concomitant radiotherapy, and board certifica-
tion of the treating physician. From the written and
electronic prescription documents, we collected all the
prophylactic orders for acute and delayed CINV,
administered by oral or intravenous route during the
first cycle of chemotherapy. Doses and schedules of
neurokinin antagonists, serotonin antagonists, dopamine
antagonists, benzodiazepines, and corticosteroids were
recorded. The expected time course of CINV was
categorized as follows: acute emesis within 24 h after
administration of chemotherapy, delayed emesis arising
24 h after chemotherapy or later, and anticipatory
emesis occurring days or hours before the beginning
of chemotherapy. The ESMO/MASCC clinical recom-
mendations cover all three categories. In this study,
anticipatory CINV was not relevant because only the
beginning of first cycle was investigated. Chemothera-
pies were divided into four groups according to their
emetogenic potential: high risk (>90% patients suffer
from nausea/vomiting without prophylaxis), moderate
risk (30–90%), low risk (10–30%), and minimal risk
(<10%). Adherence to the 2008 ESMO recommenda-
tions was determined for each patient [10]. Adherence
failure was defined (a) if a recommended antiemetic was
not prescribed, (b) if the recommended dose level was
not reached, or (c) if a non-recommended antiemetic was
prescribed. Established dexamethasone dose equivalents
for methylprednisolone were used [18]. Patient character-
istics and treatment details were summarized by standard
descriptive methods. Predictors of non-adherence with guide-
lines were investigated by univariate logistic regression
analysis; significant covariates in univariate analysis were
entered into a multivariate logistic regression model.
Results
Baseline characteristics Between November 2008 and
April 2009, 299 consecutive patients started a new
chemotherapy at our institution (Table 1). The median
age was 60 years, 178 (60%) were male, and 140 (47%)
Table 1 Baseline characteristics
Absolute Percenta
Total 299 100
Age
Median (years) 60
Range (years) 19–93
Gender
Male 178 60
Female 121 40
Setting
Outpatients 159 53
Inpatients 140 47
Diagnosis
Solid cancer 216 72
Hematologic malignancies 83 28
Intention of chemotherapy
Curative 164 55
Palliative 135 45
Line of chemotherapy
First line 267 89
Further lines 32 11
Emetogenic potential
High 97 32
Moderate 100 33
Low 54 18
Minimal 48 16
Duration of chemotherapy
Single day 148 49
Several days 151 51
Concomitant radiation
No 217 73
Yes 81 27
Treating physician
Board certified (10) 119 40
In training (9) 180 60
a Sum can deviate from 100% because of rounding
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were inpatients. Solid cancers were present in 216 (72%)
patients and hematologic malignancies in 83 (28%)
patients. Two hundred sixty-seven (89%) patients received
first-line chemotherapy, and 32 (11%) patients received
further lines of chemotherapy. The emetogenic potential of
chemotherapy was high in 97 (32%) patients, moderate in
100 (33%; including eight patients with doxorubicin and
cyclophosphamide), low in 54 (18%), and minimal in 48
(16%) patients. The most frequent therapies were cisplatin
or 5-fluorouracil (with concomitant radiation), followed
by gemcitabine, bortezomib, and rituximab, cyclophos-
phamide, doxorubicin, vincristine, and prednisone. The
duration of chemotherapy was single day in 148 (49%)
and several days in 151 (51%) patients. One hundred
nineteen (40%) patients were treated by a board-certified
physician, and 180 (60%) patients were treated by a
physician in medical oncology training supervised by a
board-certified physician.
Adherence to ESMO/MASCC recommendations Overall,
prophylaxis of acute CINV was compliant in 181 of
299 (61%) patients and non-compliant in 118 (39%)
patients (Fig. 1). Prescription of neurokinin antagonists,
serotonin antagonists, and corticosteroids for prophylaxis
of acute CINV was compliant in 83%, 82%, and 85%,
respectively. Prophylaxis of delayed CINV, assessed in the
148 patients receiving single-day chemotherapy, was
compliant in 17 of 148 (11%) patients and non-
compliant in 131 (89%) patients. Prescription of neuro-
kinin antagonists, serotonin antagonists, and corticoste-
roids for prophylaxis of delayed CINV was compliant in
70%, 11%, and 61%, respectively. Dopamine agonists and
benzodiazepines were almost exclusively prescribed as
on-demand medication; they were therefore excluded from
further analysis.
In the highly emetogenic potential group, 65 patients had
a single-day chemotherapy, and 32 patients received
chemotherapy over several days (Table 3). Prophylaxis of
acute CINV on day 1 was adherent in 69 of 97 (71%)
patients, whereas 28 of 97 (29%) patients did not receive
adherent prophylaxis, mainly caused by incorrect use of
aprepitant. The overuse of a triple antiemetic strategy
including a neurokinin antagonist, serotonin antagonist,
and corticosteroids was observed in 10 of 32 patients
undergoing high-risk chemotherapy over several days,
whereas 6 of 32 patients were treated insufficiently without
a neurokinin antagonist. In this subgroup, five patients
received procarbazine orally. In single-day treatment, all three
patients on dacarbazine and two of three patients on
doxorubicin, bleomycin, vinblastine, and dacarbazine
(ABVD) were undertreated without a neurokinin antagonist.
Adherence to recommendations for prophylaxis of delayed
CINVon days 2 and 3 was poor (20% and 35%, respectively)
because 59 of 65 patients with single-day chemotherapy
received a serotonin antagonist for several days. The
prescription of corticosteroids was generally compliant,
except that the recommended dose reduction in combination
with aprepitant was frequently not followed. Adherence on
days 4 and 5 was fair (76% and 88%, respectively).
In the moderately emetogenic potential group, 60
patients had a single-day chemotherapy, and 40 patients
received chemotherapy over several days (Table 4).
Prophylaxis of acute CINV on day 1 was compliant in 66
of 100 (66%) patients. Twenty-two patients received a
neurokinin antagonist (14 patients with single-day chemo-
therapy and eight with chemotherapy over several days).
Half of the patients treated incorrectly with a neurokinin
antagonist had hematologic malignancies and were treated
as inpatients. Seven patients were insufficiently treated on
day 1, five of them because corticosteroids were omitted.
Fig. 1 Adherence over time and
emetogenic potential. CS
corticosteroid, HT 5-
hydroxytryptamine (serotonin)
antagonist, NK neurokinin
antagonist, D1–5 days 1–5
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Adherence to recommendations for prophylaxis of delayed
CINV was poor (33% and 52%) mainly because 42 of 60
patients with single-day chemotherapy received a serotonin
antagonist on day 2 and 21 of 60 patients still on day 3
additionally to corticosteroids. On the contrary, patients
receiving temozolomide orally in a multiday regime were
undertreated in 56% of the cases, since they did not receive
corticosteroids as recommended. Adherence on days 4 and
5 was fair (78% and 78%). Among the eight patients in the
moderate group on doxorubicin and cyclophosphamide, six
had compliant prophylaxis and two patients had no neuro-
kinin antagonist because a neurokinin antagonist was
considered optional by the internal guidelines of the
gynecological oncology unit. All patients given the combi-
nation of adriamycin and cyclophosphamide inappropriate-
ly received an additional prescription of a serotonin
antagonist for delayed emesis.
Adherence to guidelines in the low emetogenic
potential group was only 6 of 54 (11%), due to the non-
compliant combination of a serotonin antagonist in
addition to corticosteroids in 39 patients (Table 5).
Seventeen of 54 (24%) patients in this group received a
serotonin antagonist against delayed emesis on day 2.
Nine patients were still treated with this medication on
day 3, and one patient received a neurokinin antagonist.
Nine patients received no antiemetics. In the minimally
emetogenic potential group, adherence was 40 of 48
(83%; data not shown). Six patients received vinorelbine
for peripheral stem cell mobilization, plus a serotonin
antagonist for prophylaxis of acute CINV, as prescribed
by the internal guidelines of the autologous transplant
unit.
Overall, 81 of 299 (27%) patients had concomitant
radiotherapy, including 36 patients on cisplatin. Although
radiotherapy by itself can be emetogenic, the 2008 ESMO
recommendations did not address this issue specifically.
Out of this group, one patient with moderately emetogenic
chemotherapy was overtreated by receiving a neurokinin
antagonist, whereas four patients with highly emetogenic
chemotherapy did not receive any neurokinin antagonist.
All 26 patients with radiotherapy and concomitant mini-
mally emetogenic chemotherapy correctly received no
prophylaxis.
Predictors of non-adherence Logistic regression was used
to identify factors associated with adherence to ESMO/
MASCC clinical recommendations for prophylaxis of
CINV (Table 2). In the univariate analysis, low and
moderate emetogenic potential predicted non-adherence.
On the contrary, higher age, solid tumor type, and inpatient
were associated with better adherence. In the multivariate
analysis, younger age was associated with poor adherence,
whereas hematologic neoplasia, men, and outpatient were
twice at risk of non-adherence. High emetogenic potential
was found to be tightly correlated with inpatient treatment.
Only 16 of 97 patients receiving highly emetogenic
chemotherapy were outpatients. Therefore, emetogenic
potential was not an independent predictor of adherence
in the multivariate analysis.
Discussion
Our study showed that during the study period,
adherence to ESMO/MASCC recommendations for
prophylaxis of CINV at our institution was not optimal.
The major deviation from the 2008 ESMO clinical
recommendations was an overuse of serotonin antago-
nists for prophylaxis of acute CINV in patients with low
emetogenic chemotherapy and overuse of serotonin
antagonists for prophylaxis of delayed CINV in patients
with highly and moderately emetogenic chemotherapy.
A clear differentiation between standby medication and
fixed prescription was not recognizable, and it is
therefore possible that our study overestimated the use
of serotonin antagonists for prophylaxis of delayed
CINV. In some patients with moderately emetogenic
chemotherapy, overuse of neurokinin antagonists was
also noted. Although not technically compliant with the
ESMO guidelines, the treatment received by these
patients cannot be regarded as inadequate as serotonin
antagonists are likely to be effective with low emeto-
genic chemotherapy. In their recent study, Rapoport et
al. also show the benefit of including neurokinin
antagonists as part of the standard therapy for moderate
emetogenic chemotherapy [19]. Most patients on apre-
pitant received corticosteroids at full doses, despite the
recommended dose reduction to 50–75% in the 2008
ESMO recommendations [10]. In the updated 2009
ESMO recommendations, published in May 2009 after
the registration period of our study, this specific point
was deleted, and a total dexamethasone dose of 12 mg
was mentioned [11]. In 2010, a guideline update for
MASCC and ESMO was published, including a compre-
hensive review of the literature and recommendations for
prevention of radiotherapy-induced nausea and vomiting
[12].
At our institution, adherence to ESMO recommenda-
tions in patients receiving bleomycin, etoposide, doxo-
rubicin, cyclophosphamide, vincristine, procarbazine,
and prednisone (BEACOPP) or ABVD chemotherapy
was poor because only few of these patients received a
neurokinin antagonist. Although procarbazine and
dacarbazine are classified as highly emetogenic, our
own experience supports the view that most patients
receiving BEACOPP or ABVD do not experience CINV
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when the neurokinin antagonist is omitted. Future
recommendations should include more information on
evidence-based indications for neurokinin antagonists
versus situations where the benefit is less well-known.
Focusing on the highly emetogenic group, we found
out that more than 70% of patients were treated
correctly by receiving a triple regime: a neurokinin
antagonist, a serotonin antagonist, and corticosteroids.
The lack of adherence on day 2 was primarily due to the
prescription of a serotonin antagonist, which in this
setting probably contributes minimally to antiemetic
control. Nevertheless, these results contrast with two
older studies from the USA, reporting frequent omission
of corticosteroids to prevent delayed CINV. The study
by De Angelis et al. was published as an abstract, and
the study by Mertens et al. was published in a peer-
reviewed journal [15, 16]. Mertens et al. assessed the
prophylaxis of CINV in 125 patients with highly
emetogenic chemotherapy. According to internal guide-
lines, based on the 1999 ASCO recommendations, 73%
of the patients in the Mertens study did not receive
adequate prophylaxis [20]. Only 25% of patients correct-
ly received corticosteroids for prophylaxis of delayed
CINV, and 64% of the patients experienced nausea during
the first 5 days. Our study, however, showed frequent
overuse of antiemetics for CINV prophylaxis. This could
be clinically and economically relevant. Although we
collected data from a large set of patients, our study was
limited because it was unicentric and retrospective.
However, our results are very consistent with the study
by Roila et al. [21], which reported on the adherence in
77 Italian centers. Although the guidelines and some of
the prophylactic medications have been modified since
2000, there still remains undertreatment in acute prophy-
laxis in the high-risk group and overtreatment in acute
and delayed prophylaxis in the moderate-, low-, and
minimal-risk groups. We encourage other centers to
conduct similar studies, to shed more light on the
magnitude of the problem.
An important question arising from our study is how
to improve the current situation, since adherence to the
guideline is related with a better control of CINV. In a
cohort study, O’Kane shows that adhering to MASCC
antiemetic guidelines significantly reduces CINV with
cisplatin and oxaliplatin [22]. Our results suggest that
adherence was not related to board certification of the
treating physician. All except one board-certified medical
oncologist at our institution had previously taken the
ESMO exam. All physicians in training had previously
undergone periodical education in supportive care and
were supervised by board-certified physicians. Our study
emphasizes the need for continued education. However,
Mertens et al. demonstrated that education alone did not
substantially improve adherence [16]. In their study,
physician adherence was enhanced when delayed CINV
occurred due to omission of prophylaxis. Symptoms
specifically related to an overuse of antiemetics (for
instance, constipation, dizziness, or fatigue) such as
pointed out in our study fail to play this part, since they
can also be caused by cancer itself or by chemotherapy.
Underuse of antiemetics will predictably lead to patient
reports and complaints at follow-up visits, and such
patient-reported outcome measures have been shown to
be effective in changing the prescription practice of
physicians. Patients reporting their symptoms in a self-
managed diary could improve symptom control and
patient compliance. Overprescription of antiemetics is,
however, much less likely to be detected by patients,
since overuse can only be detected if in patients without
CINV a given regime of antiemetics is deliberately
tapered to the minimally required dosage level to
prevent this type of side effect. In clinical practice, both
patients and physicians are somewhat reluctant to fine-
tune the dosage of antiemetics during follow-up visits in
this manner, and successful albeit overdosed CINV
prophylaxis is likely to be maintained. Other studies
have shown that pharmacy- or nursing-controlled pre-
scriptions and software ordering tools can enhance
Table 2 Logistic model coefficients table for overall adherence
Univariate analysis Multivariate logistic regression analysis
OR RR 95% CI P (Wald) OR OR 95% CI P (Wald)
Age 0.982 0.966–0.998 0.027 0.981 0.964–0.998 0.029
Gender (female vs. male) 0.496 0.304–0.808 0.005 0.484 0.291–0.806 0.005
Physician (non-certified vs. certified) 1.062 0.662–1.705 0.802
Emetogenic potential (high vs. low+moderate) 0.505 0.3–0.849 0.009 0.766 0.392–1.497 0.436
Tumor type (hematologic vs. solid) 1.829 1.097–3.049 0.020 2.151 1.19–3.887 0.011
Inpatient vs. outpatient 0.496 0.309–0.799 0.004 0.457 0.25–0.836 0.011
OR odds ratio, RR relative risk, CI confidence interval
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adherence [13, 23]. As a consequence, we are currently
implementing software-based prophylaxis of CINV at our
institution, to reduce overuse and potential harm in our
patients. This software automatically adds the appropriate
antiemetics to the chemotherapy which is prescribed.
Accreditation programs, including the ESMO program for
the Integration of Oncology and Palliative Care, may
offer a chance to introduce such measures to a broader
community [24].
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Appendix
Table 3 Adherence in patients with highly emetogenic chemotherapy
Total
(N=97)
Single-day
(N=65)
Several days
(N=32)
Day 1
- overall 69 71% 53 82% 16 50%
- NK 70 72% 54 83% 16 50%
- HT 94 97% 64 98% 30 94%
- CS 96 99% 65 100% 31 97%
Day 2
- overall 19 20% 6 9% 13 41%
- NK 70 72% 54 83% 16 50%
- HT 30 31% 6 9% 24 75%
- CS 94 97% 62 95% 32 100%
Day 3
- overall 34 35% 22 34% 12 38%
- NK 70 72% 54 83% 16 50%
- HT 56 58% 34 52% 22 69%
- CS 83 86% 51 78% 32 100%
Day 4
- overall 74 76% 55 85% 19 59%
- NK 95 98% 65 100% 30 94%
- HT 87 90% 62 95% 25 78%
- CS 84 87% 57 88% 27 84%
Day 5
- overall 85 88% 65 100% 20 63%
- NK 95 98% 65 100% 30 94%
- HT 92 95% 65 100% 27 84%
- CS 91 94% 65 100% 26 81%
CS corticosteroid; HT 5-hydroxytryptamine (serotonin) antagonist; NK
neurokinin antagonist
Table 4 Adherence in patients with moderately emetogenic
chemotherapy
Total
(N=100)
Single-day
(N=60)
Several days
(N=40)
Day 1
- overall 66 66% 42 70% 24 60%
- NK 76 76% 44 73% 32 80%
- HT 95 95% 58 97% 37 93%
- CS 94 94% 59 98% 35 88%
Day 2
- overall 33 33% 14 23% 19 48%
- NK 76 76% 44 73% 32 80%
- HT 49 49% 18 30% 31 78%
- CS 60 60% 34 57% 26 65%
Day 3
- overall 52 52% 28 47% 24 60%
- NK 76 76% 44 73% 32 80%
- HT 75 75% 39 65% 36 90%
- CS 77 77% 46 77% 31 78%
Day 4
- overall 78 78% 50 83% 28 70%
- NK 90 90% 52 87% 38 95%
- HT 85 85% 50 83% 35 88%
- CS 81 81% 50 83% 31 78%
Day 5
- overall 78 78% 49 82% 29 73%
- NK 90 90% 52 87% 38 95%
- HT 85 85% 50 83% 35 88%
- CS 82 82% 51 85% 31 78%
CS corticosteroid; HT 5-hydroxytryptamine (serotonin) antagonist; NK
neurokinin antagonist
Total (N=54)
Day 1
- overall 6 11%
- NK 53 98%
- HT 15 28%
- CS 24 44%
Day 2
- overall 37 69%
- NK 53 98%
- HT 37 69%
- CS 51 94%
Day 3
- overall 45 83%
- NK 53 98%
- HT 45 83%
- CS 51 94%
Table 5 Adherence in patients
with low emetogenic
chemotherapy
CS corticosteroid; HT 5-
hydroxytryptamine (serotonin)
antagonist; NK neurokinin
antagonist
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